United Kingdom – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Thu, 09 May 2024 17:23:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 UK’S Medical Cannabis Boom: Patients, Demand and Consumption Surge to All-Time Highs – With a Record Number of Private Clinics https://mjshareholders.com/uks-medical-cannabis-boom-patients-demand-and-consumption-surge-to-all-time-highs-with-a-record-number-of-private-clinics/ Thu, 09 May 2024 17:23:08 +0000 https://cannabisfn.com/?p=2974387

Ryan Allway

May 9th, 2024

News, Top News, Top Story


[PRESS RELEASE — LONDON, UK, 9 May, 2024] — The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to ‘unusually high’ consumption volumes on a per-patient basis.

By the end of 2024, for example, 62,960 patients are forecasted to be using medical cannabis in the UK, generating €240 million (£205 million) in sales, meaning the average medical cannabis patient in the UK will consume €3,811-worth (£3,261) of medical cannabis per year, or €318-worth (£272) per month.

Compare this to Germany, with the largest medical cannabis market and patient population in Europe, where the average medical cannabis patient will consume €1,563 (£1,342) of medical cannabis per year, or €130 (£112) per month.

Average prices paid per gram of dried medical cannabis flower or millilitre of oil are lower in the UK than in Germany, so the primary factor contributing to this staggering 144% difference in spend is an even larger divergence in consumption volumes.

These findings have been published today in a new report from UK-based cannabis data and intelligence company, Prohibition Partners.

Why So High?
Speaking about the potential reasons for the high consumption rates in the UK compared to other European countries, Lawrence Purkiss, senior analyst at Prohibition Partners, said: “The comparatively high per-patient consumption rates in the UK are at least in part a consequence of the fact that the market is entirely private and self-paid. The financial incentives within the system are geared towards high prescription volumes, unlike in Germany where at least 50% of patients have their medical cannabis costs reimbursed under public healthcare.”

Stephen Murphy, co-founder and CEO of Prohibition Partners, added: “The findings in the 9th Edition of ‘The European Cannabis Report’ highlight an intriguing trend: Patients in the UK are consuming more than their counterparts in other European markets. Since the legalisation of medical cannabis in 2018, private companies have aimed to enhance options and accessibility for patients. However, due to supply chain restrictions and costs, patients often opt for volume over frequency. This underscores the need for continued efforts to streamline regulations and improve affordability to ensure patients’ needs are adequately met.”

UK Market & Patient Explosion
Growth in the total number of medical cannabis patients in the UK is also forecast to soar over the next four years. By 2028, the number of medical cannabis patients in the UK is expected to increase by 124% to approximately 141,000 patients (up from approx. 63,000 by the end of 2024).

By comparison, in Germany the growth rate is just 24%, with approximately 346,000 medical cannabis patients anticipated by 2028 (up from approx. 278,000 by the end of 2024).

Together, Germany and the UK will account for 77% of all medical cannabis sales and patients in Europe by 2028 (Germany 50%, UK 27%).

Private Clinics Driving Growth
Although medical cannabis was legalised in the UK in November 2018 and is technically available on prescription through the National Health Service (NHS), patient access to medical cannabis in the UK is almost exclusively facilitated by private clinics.

These clinics are supplied by large medical cannabis distributors like Curaleaf Laboratories. Of the growth in sales and patient population in the UK, Jonathan Hodgson, CEO of Curaleaf Laboratories, said: “The beginning of 2024 has already shown a tremendous level of growth, with a record number of UK private clinics now providing medical cannabis treatment for lower appointment costs than ever before. More formulations and dosage forms have entered the market, such as pastilles and liquid vape cartridges, broadening the treatment options available for specialists to prescribe for patients.”

These medical cannabis findings have been published today in a new report – “The European Cannabis Report: 9th Edition” – by UK-based cannabis data and intelligence firm, Prohibition Partners. A version of the report is now available to download for free via the Prohibition Partners website.

ABOUT PROHIBITION PARTNERS
Prohibition Partners is a data, media and tech company operating in the fast-growing legal cannabis industry. We provide the industry with specialist information and data analytics.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Decibel Expands Global Footprint with Agreement to Supply Medical Cannabis to 4C LABS for Distribution in the United Kingdom https://mjshareholders.com/decibel-expands-global-footprint-with-agreement-to-supply-medical-cannabis-to-4c-labs-for-distribution-in-the-united-kingdom/ Wed, 30 Aug 2023 14:48:03 +0000 https://cannabisfn.com/?p=2974021

Ryan Allway

August 30th, 2023

News, Top News


CALGARY, ABAug. 30, 2023 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and extract manufactured products, is pleased to announce that it has expanded its global footprint by entering into a supply agreement (the “Agreement”) to provide premium dried medical cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products for human health in the United Kingdom and Channel Islands (the “UK”).

Key Highlights

  • Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients
  • Decibel to grant strain exclusivity of rare and unique cultivars to be distributed by 4C LABS
  • 3-year supply agreement
  • Initial shipment expected before year end
  • Minimum purchase commitments achieve exclusivity over certain genetics and QWEST brand in the UK

“We are excited to partner with 4C LABS, a leading organization in the growing medical cannabis industry in the UK, that echoes Decibel’s commitment to quality and patient care. Not only will this unlock a strong partnership and a new market for Decibel’s craft cannabis products, it also sets the stage for further growth into other European markets,” said Adam Coates, Chief Revenue Officer. “Decibel’s success with Qwest flower products in Canada and in Israel’s medical market reinforces the demand for premium cannabis products and the reputation we have built to service that demand.”

“4C LABS is building a patient focused best-in-class product line for the UK & Channel Islands, the Qwest craft flower line strengthens the top end of the 4C LABS product offerings. Decibel’s innovative craft quality Qwest flower products will fill an empty segment in the UK market and bring a world class BC Cannabis product to UK patients,” said Greg Dobbin, CEO 4C LABS. “Decibel’s success in Canada, the most competitive cannabis market in the world, is a product of hard work, innovation and attention to detail, qualities that will resonate with UK patients.”

About Decibel

Decibel is a consumer-focused cannabis company focused on delivering products that delight customers through a commitment to robust innovation and product quality. Leading brands General Admission, Qwest, and Vox are among its portfolio sold both across Canada and beginning to extend towards new countries to create a global footprint. Decibel operates a processing and manufacturing facility in Calgary, Alberta, and two cultivation facilities in Creston, British Columbia, and Battleford, Saskatchewan.

About 4C LABS

4C LABS is a patient focused healthcare, technology, and pharmaceutical company concentrating on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products (“CBMPs”) for human health. 4C LABS is committed to advancing scientific research, as well as enabling the regulation, distribution and prescribing of CBPMs in the UK and Channel Islands. Its work with leading scientists, specialist physicians, and pharmacists is underpinned with disruptive technologies that are driving an approach to treatment that prioritizes patients and evidence over stigma. 4C LABS works closely with Drug Science, the Cannabis Industry Council (CIC), The Medicines and Healthcare Products Regulatory Agency (MHRA) and the Care Quality Commission (CQC) to catalyze safe, regulated change in the medical landscape. 4C LABS is fully licensed in the UK with MS WDA, Schedule 1 Narcotics and Production licenses.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, the timing of the initial shipment; expectations with respect to the impact the Agreement will have on the Company’s business; expectations regarding international markets and the Company’s position therein; the Company’s ability to grow its brands into new and innovative territories as well as product formats, variations and other business plans and expectations.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: satisfaction of all international regulatory requirements, including applicable product testing; risks relating to delays; other regulatory changes and impacts; capital requirements; construction impacts; displacement requirements; global macro-economic events, conditions and factors; the ability to obtain and maintain licenses to retail cannabis products; review of the Company’s production facilities by Health Canada and maintenance of licenses (including any amendments thereto) from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis, international export rules and regulations; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; general business, economic, competitive, political and social uncertainties; the satisfaction of conditions precedent under the Company’s credit facilities; and the delay or failure to receive board, regulatory or other approvals, including any approvals of the TSX Venture Exchange, as applicable.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

These forward-looking statements are made as of the date of this press release and the Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Decibel Cannabis Company Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
High Tide Subsidiary Blessed CBD Launches Subscribe-and-Save Discount Program in the U.K. Market https://mjshareholders.com/high-tide-subsidiary-blessed-cbd-launches-subscribe-and-save-discount-program-in-the-u-k-market/ Wed, 25 May 2022 14:51:51 +0000 https://www.cannabisfn.com/?p=2948762

In addition to improving convenience and savings for members, the launch of the Wellness Club will further solidify customer loyalty and brand equity for Blessed in the U.K.  Because Wellness Club members will be enrolled in a service that auto-renews their orders, Blessed CBD expects to boost its lifetime value per customer beyond current levels. The Wellness Club will also allow Blessed CBD to grow a recurring revenue stream that will be much more predictable than the current system of customers being required to manually place their orders. Although the Wellness Club will initially only be available in the United Kingdom, Blessed CBD intends to expand the program into Germany in the future.

“The launch of Blessed CBD’s Wellness Club, as well as NuLeaf Naturals’ revamped Subscribe-and-Save program, are further examples of the cross-platform synergies that High Tide has been able to develop as a result of our forward-thinking acquisition strategy. Over the past year, we have acquired businesses that are well-positioned to cultivate recurring and predictable revenue streams through the innovative use of value-based loyalty and subscription programs,” said Raj Grover, President and Chief Executive Officer of High Tide. “As we continue to build upon our diversified cannabis ecosystem, I expect that we will be able to drive further revenue growth with minimal capital cost by leveraging our organic innovations and applying them across our various platforms. Today’s announcement also further demonstrates our commitment to expanding our presence, customer bases, and revenues through legal activities in markets such as the U.K. and the U.S., where full cannabis legalization has not yet come to pass.  We look forward to launching additional organic innovations across our portfolio,” added Mr. Grover.

NULEAF NATURALS LAUNCHES REVAMPED SUBSCRIBE-AND-SAVE PROGRAM

The Company also announced today that its United States-based subsidiary, NuLeaf Naturals, has launched a revamped Subscribe-and-Save program, based on the success of the similarly-named and designed subscription program launched by fellow U.S. Subsidiary, FAB CBD, in March of 2022. Under this program, customers will be able to customize their orders each month to suit their specific needs, with items from across all NuLeaf Naturals product lines including oils, softgels, topicals, and pet treats. Customers will also have the ability to customize their delivery frequency for each individual product in their order, allowing delivery frequencies to optimally match each customer’s needs for every product. In addition, by opting-in to the Subscribe-and-Save discount program, customers will receive a 20% discount for life on all NuLeaf Naturals products that they purchase, similar to what is offered by FAB CBD in the U.S. market currently.

ABOUT HIGH TIDE

High Tide is a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets. The Company is the largest non-franchised Canadian retailer of recreational cannabis as measured by revenue, with 122 current locations spanning OntarioAlbertaManitoba, and Saskatchewan. High Tide was featured in the third annual Report on Business Magazine’s ranking of Canada’s Top Growing Companies in 2021 and was named as one of the top 10 performing diversified industries stocks in the 2022 TSX Venture 50™. The Company is also North America’s first and only cannabis discount club retailer, featuring Canna Cabana, Meta Cannabis Co., and Meta Cannabis Supply Co. banners, with additional locations under development across the country. High Tide’s portfolio also includes retail kiosk and smart locker technology – Fastendr™. High Tide has been serving consumers for over a decade through its established e-commerce platforms including Grasscity.com, Smokecartel.com, Dailyhighclub.com, and Dankstop.com and more recently in the hemp-derived CBD space through Nuleafnaturals.com, FABCBD.com, BlessedCBD.co.uk, and BlessedCBD.de, as well as its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For more information about High Tide Inc., please visit www.hightideinc.com, its profile page on SEDAR at www.sedar.com, and its profile page on EDGAR at www.sec.gov.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this news release are forward-looking information or forward-looking statements. Such information and statements, referred to herein as “forward-looking statements” are made as of the date of this news release or as of the date of the effective date of information described in this news release, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as “outlook”, “expects”, “intend”, “forecasts”, “anticipates”, “plans”, “projects”, “estimates”, “envisages, “assumes”, “needs”, “strategy”, “goals”, “objectives”, or variations thereof, or stating that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements. Forward-looking statements in this news release include statements relating to: the expected financial benefits of the Blessed CBD and NuLeaf Naturals subscription services, including the Company’s expectation that the subscription service will boost the lifetime value per customer and will allow the Company to cultivate a more predictable recurring revenue stream, Mr. Grover’s statements with respect to further growing the Company’s revenues by leveraging its diversified cannabis ecosystem through organic innovations and without added capital cost, the Company’s strategy as a parent company to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value.

Such forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to customer demand for the Blessed CBD and NuLeaf Naturals subscription services, the Company’s ability to further grow the Company’s revenues by leveraging its diversified cannabis ecosystem without added capital cost, or at all, the Company’s ability to extend and strengthen its integrated value chain while providing a complete customer experience and maximizing shareholder value, the Company’s ability to execute on its business plan and that High Tide will receive one or multiple licenses from Alberta Gaming, Liquor & Cannabis, British Columbia’s Liquor Distribution Branch, Liquor, Gaming and Cannabis Authority of Manitoba, Alcohol and Gaming Commission of Ontario or the Saskatchewan Liquor and Gaming Authority permitting it to carry on its Canna Cabana Inc. business. High Tide considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that any one or more of the government, industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

The forward‐looking statements contained herein are current as of the date of this news release. Except as required by law, High Tide does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. Any and all forward-looking statements included in this news release are expressly qualified by this cautionary statement, and except as otherwise indicated, are made as of the date of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

SOURCE High Tide Inc.

]]>
Flora Growth Expands Into U.K. and Central American Markets with Sales to New International Distribution Partners https://mjshareholders.com/flora-growth-expands-into-u-k-and-central-american-markets-with-sales-to-new-international-distribution-partners/ Fri, 14 May 2021 19:39:42 +0000 https://www.cannabisfn.com/?p=2920413

Ryan Allway

May 14th, 2021


TORONTO, ONTARIO – May 14, 2021 — Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, today announced it has expanded into the United Kingdom (the “UK”) and Costa Rica, fulfilling initial orders from two new distributors. Specifically, Flora’s Kasa Wholefoods division (“Kasa”) has fulfilled an initial shipment of Mambe juices to a distributor for the Central American food and beverage market, while an initial shipment of Almost Virgin, Mind Naturals and Mambe products was fulfilled to the UK.  

UK Expansion

Flora is pleased to announce that it has completed an initial shipment of products from its Mind Naturals, Almost Virgin, and Mambe brands to the UK. This order is a significant milestone for Flora, as it represents the Company’s first shipment of CBD-containing products into Europe. Going forward, Flora intends to expand on its relationship in the UK to bring its entire product portfolio into the UK market and into adjacent markets throughout the European Union.

Central American Expansion

In April 2021, Kasa signed a distribution agreement with GMD Latinoamérica, a Costa Rica-based distributor for the Central American food and beverage market. Exports will begin in Puerto Limon, Costa Rica. Kasa is also in the process of registering additional product lines of its portfolio for the Central American and Caribbean markets.

“Flora Growth’s expansion into the UK and Central America aligns perfectly with our strategy of aggressive expansion into new markets, as we continue to establish our premium brands’ international presence,” said Flora CEO Luis Merchan. “We look forward to working with our new distribution partners in both Europe and Central America and hope to expand even further into both continents in the coming months.”

About Flora Growth’s Premium Product Portfolio 

Mind Naturals is the inaugural brand from the Flora Beauty division; it is an inclusive brand that uses premium CBD and quality clean ingredients to craft an assortment of natural skincare essentials. The brand consists of 11 unique products and caters to the mass-market and is sold across e-commerce channels in Colombia and the United States. Mind Naturals products are also being distributed with the largest Latin American retailer, Falabella across 15 of the highest-traffic retail centres in Colombia, with the opportunity to expand across Falabella’s 111-store portfolio. Mind Naturals products are also available through online channels across Falabella’s e-retailer Linio, which sees over 290 million visitors per year and on Fallabella.com.

Mind Naturals was developed by Paulina Vega, a renowned figure in the fashion and beauty industry. She is a former Miss Universe and Miss Colombia and a proud ambassador for Latin Americans. With more than 5.7 million Instagram followers, Mrs. Vega will help drive sales through e-commerce channels. 

Mambe is the primary brand behind Flora’s Kasa Wholefoods division. Mambe’s products are made in Colombia using natural and sustainable methods from responsibly sourced exotic Amazonian fruits. Mambe has over 980 distribution points within Colombia, which are expected to grow to 1,200+ in 2021. This includes Tostao’ Café & Pan, the Colombian equivalent of Starbucks, Mambe’s largest customer. Mambe’s other products include exotic fruits coated with chocolate, chocolate bars, and dried fruits and fruit pulp from the Amazon. The brand contains both CBD and non-CBD products. The Mambe brands’ founder and ambassador is Laura Londoño, the award-winning Latin-American actress with a strong following of more than 1.3 million Instagram followers. 

Almost Virgin is the second brand under Flora’s Kasa Wholefoods division and was conceived to satisfy the curious minds of our bold and sensual customers. The brand’s collection of botanical sexual wellness products is designed to enhance sexual experiences and to increase awareness about human bodies and health while helping relieve stress from today’s fast-paced and demanding life. The Almost Virgin brand is available for sale through e-commerce channels across the United States and Colombia. 

About Flora Growth Corp.

Flora is a cannabis company that will leverage natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.floragrowth.ca or follow @floragrowthcorp on social for more information.

Investor Relations Contact:

Evan Veryard
+1 416 571 9037
[email protected]

Public Relations Contact:
Cassandra Dowell
+1 (847) 271-3443
[email protected]

Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.  We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities.  You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business.  These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions.  The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us.  We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>